Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00968396
Recruitment Status : Withdrawn
First Posted : August 31, 2009
Last Update Posted : April 5, 2013
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
The goal of this clinical research study is to learn if cleaning the stem cells of a patient who has multiple myeloma (MM) with the bone marrow of a relative will make a cell product capable of replacing the bone marrow after standard treatment with chemotherapy.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Procedure: Apheresis Procedure: Stem Cell Transplantation Drug: Melphalan Phase 2

  Hide Detailed Description

Detailed Description:

A transplant of one's own bone marrow stem cells is part of a standard treatment for MM. Because MM comes from the bone marrow, stem-cell products from the bone marrow can have tumor cells mixed in them when they are transplanted. This may cause the disease to return after transplant. This study will learn about a method of cleaning, or "purging," the MM tumor cells from the stem cells by using the bone marrow of a relative.

Study Drugs:

Melphalan is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to die.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will be given G-CSF twice a day through a needle under the skin on Days 1-5 to move stem cells from out of the bone marrow and into the blood.

You will receive melphalan through a needle in your vein over 30 minutes each time on the 2 days directly before you receive the stem cell transplant.

Stem Cell Collection, Purging, and Transplantation:

On Day 5, stem cell collection will begin. You will have a central venous catheter (CVC - a sterile, flexible tube) placed into a vein in your chest while you are under local anesthesia. Your doctor will explain this procedure to you in more detail, and you will be required to sign a separate consent form for this procedure.

Blood will be removed from your body through the CVC and passed through a machine that separates stem cells from the other cells. The stem cells will be frozen for storage, and the blood will be returned to your body. This 3-hour process is called apheresis. This process will be done 1 time a day for 1-6 days, or until enough stem cells are collected.

Your stem cells will be placed in a sterile container, where they will grow and multiply with donated stem cells from a relative. If there are enough cells after 2 weeks, the cells will be transplanted back into the body. If there are not enough cells after the 2 weeks of growing with the donor's stem cells, they will be combined with a sample that was set aside at your initial collection and then transplanted back into the body.

Study Visits:

One (1), 2, and 6 months after the transplant, blood (about 2 teaspoons) will be drawn for routine tests and to check the status of the disease.

Six (6) months after the transplant, you will also have a bone marrow aspirate/biopsy to check the status of the disease.

Length of Study:

You will remain on study until 12 months after the transplant. You will be taken off study if the disease gets worse or needs further treatment.

End-of-Treatment Visit:

Twelve (12) months after the transplant, you will have your end-of-treatment visit. At this time, the following tests and procedures will be performed:

  • Blood (about 2 teaspoons) will be drawn for routine tests and to check the status of the disease.
  • You will have a bone marrow aspirate/biopsy.
  • You will have x-rays taken of your bones.

This is an investigational study. Melphalan is FDA approved and commercially available for the treatment of MM. While receiving a stem-cell transplant is standard treatment for MM, cleaning (purging) the stem-cell product is investigational.

Up to 25 recipients will take part in this study. All will be enrolled at M. D. Anderson


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
Study Start Date : February 2013
Estimated Primary Completion Date : February 2015


Arm Intervention/treatment
Experimental: Stem Cell Collection + Transplantation
Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
Procedure: Apheresis
On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.

Procedure: Stem Cell Transplantation
Co-culture Stem Cell Infusion on Day 0.

Drug: Melphalan
100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
Other Name: Alkeran




Primary Outcome Measures :
  1. Neutrophil Engraftment Rate [ Time Frame: 28 Days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with multiple myeloma who have relapsed after an autologous transplant or with a chemosensitive relapse more than one year post initial therapy
  2. Age 18 to 75 years
  3. Left ventricular ejection fraction >/= 40%. No uncontrolled arrhythmias
  4. FEV1, FVC and DLCO >/= 40%. No symptomatic pulmonary disease
  5. Serum bilirubin </= 2 x upper limit of normal, SGPT </= 4 x upper limit of normal
  6. HIV-negative
  7. Negative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization
  8. Patient or guardian able to sign informed consent
  9. Marrow-MSC Donor Requirements: patients must have a family member who is matched at 2, 3, or 4 HLA antigens and willing to donate 80-100 ml or bone marrow for MSC generation

Exclusion Criteria:

  1. International Staging System (ISS) stage I at diagnosis (beta-2 microglobulin < 3.5 mg/L and albumin >/= 3.5 g/dL)
  2. Patients with an apheresis collection </= 7 x 10e6 CD34+/Kg
  3. A fully matched related donor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00968396


Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Layout table for investigator information
Study Chair: Yago Nieto, MD, PHD UT MD Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00968396     History of Changes
Other Study ID Numbers: 2007-0886
First Posted: August 31, 2009    Key Record Dates
Last Update Posted: April 5, 2013
Last Verified: April 2013
Keywords provided by M.D. Anderson Cancer Center:
Myeloma
Ex-Vivo Depletion of Myeloma Cells
Peripheral Blood Progenitor Cell Grafts
PBPC
Stem Cell Transplant
Bone marrow stem cells
Melphalan
Alkeran
Apheresis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Melphalan
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs